Problem or mechanism
NHS, UK or peer-reviewed evidence establishes that the underlying discrepancy, oversupply or pathway opportunity can occur.
Every Sitora product follows the same evidence discipline, but each keeps its own denominator, safety boundary and definition of success.
Use source-system data, timestamps, supply history and pathway activity.
Identify a medication discrepancy, avoidable-supply signal or resource opportunity.
Clinical and operational experts confirm that the signal is real and appropriate to act on.
Assign the smallest governed action to a named owner.
Measure closure, dispensing outcome or actual resource recovery and classify the benefit correctly.
NHS, UK or peer-reviewed evidence establishes that the underlying discrepancy, oversupply or pathway opportunity can occur.
Ownership, acknowledgement, prioritisation, reconciliation, pre-dispensing review or whole-pathway measurement.
Observed outcome, safety, workload, reusable capacity and any validated financial effect in the participating service.
We do not claim one national medicines-waste number, that every unresolved discrepancy causes harm, that every repeat prescription is unnecessary, that published resource effects automatically apply locally, or that released workforce time automatically becomes cash. Those questions require local measurement.